Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2051 Results for "
ANDS
" in MedChemExpress (MCE) Product Catalog:
Products (2051)
2051 Results for "ANDS" in MCE Product Catalog:
Cat. No.: HY-184486
CAS No.: 16781-09-2
Synonyms: 1-Amino-8-naphthol-2,4-disulfonic acid
Target:
Research Areas:
ANDS (1-Amino-8-naphthol-2,4-disulfonic acid) is an orally active inhibitor of CaMKP (IC50 = 6.4 μM; Ki = 3.6 μM) and CaMKP‑N (IC50 = 6.6 μM) . ANDS binds unacetylated p53 and restores p53 activity by disrupting ANP32B-p53 interaction. ANDS inhibits chronic myeloid leukemia (CML) cell proliferation, impairs leukemic stem cells (LSC) function and prolongs survival in CML mouse model while sparing normal progenitor cells. ANDS can be used to study the eradication of LSCs and the overcoming of tyrosine kinase inhibitor (TKI) resistance in CML . ANDS can be used to study breast cancer .
168
168 Publications Verification
Synonyms: Adenosine 5'-triphosphate disodium salt, 100 mM Solution, PCR Grade
62
62 Cited Publications
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .
52
Target:
Research Areas:
Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
52
Target:
Research Areas:
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
26
Category:
Disease Research Antibacterial Infection Microorganisms Macrolide Antibiotics Antibiotics Animal Husbandry Mammalian Cell Culture Anticancer Disease Research Fields
Target:
26
Target:
Erythromycin lactobionate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin lactobionate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin lactobionate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
26
Category:
Infection Microorganisms Macrolide Antibiotics Antibiotics Disease Research Antibacterial Anticancer Disease Research Fields
Target:
24
Research Areas:
N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer and/or degenerative disease. N-Nitroso-N-methylurea is also a precursor in the synthesis of diazomethane .
14
14 Cited Publications
Cat. No.: HY-W016319
CAS No.: 138-15-8
Target:
Research Areas:
12
12 Cited Publications
Synonyms: MC-207,110 dihydrochloride; Phe-Arg-β-naphthylamide dihydrochloride
10
10 Cited Publications
Cat. No.: HY-N0473A
CAS No.: 69847-45-6
Target:
7
7 Cited Publications
Cat. No.: HY-W011391A
CAS No.: 7300-59-6
Target:
Research Areas:
7
7 Cited Publications
Cat. No.: HY-W345421
CAS No.: 122864-94-2
Target:
Research Areas:
5
5 Cited Publications
Target:
5
5 Cited Publications
Cat. No.: HY-W009203
CAS No.: 30925-07-6
5
5 Cited Publications
Cat. No.: HY-W142119
CAS No.: 2792-66-7
Target:
Research Areas:
4
4 Cited Publications
Research Areas:
GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor with an IC50 of 49.7 μM. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research .
4
4 Cited Publications
Synonyms: UTP trisodium dihydrate; Uridine 5'-triphosphate trisodium dihydrate
4
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
